MARKET

FIXX

FIXX

Homology Medicines
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.72
+0.01
+0.15%
Pre Market: 6.86 +0.14 +2.08% 09:05 04/23 EDT
OPEN
6.71
PREV CLOSE
6.71
HIGH
6.84
LOW
6.62
VOLUME
1.09K
TURNOVER
--
52 WEEK HIGH
17.34
52 WEEK LOW
6.21
MARKET CAP
382.13M
P/E (TTM)
-2.3928
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15)
Benzinga · 3d ago
Companies Like Homology Medicines (NASDAQ:FIXX) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Simply Wall St. · 3d ago
Homology Medicines Announces Presentations at ACMG Annual Clinical Genetics Meeting
- Data From Company’s PKU and Hunter Syndrome Gene Therapy Programs Featured in Presentations - BEDFORD, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today two pres...
GlobeNewswire · 04/14 12:58
The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13)
Benzinga · 04/14 11:51
Homology Medicines promotes Tim Kelly to COO
Homology Medicines (FIXX) announces the promotion of Tim Kelly to chief operating officer from previously held role of the company's chief technical operating officer.The change in effective immediately.Prior to joining Homology
Seekingalpha · 04/12 12:56
Press Release: Homology Medicines Announces Promotion of Tim Kelly to Chief Operating Officer
Dow Jones · 04/12 12:31
Homology Medicines Names Tim Kelly Oper Chief
Homology Medicines Names Tim Kelly Oper Chief
Dow Jones · 04/12 12:30
The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 8)
Benzinga · 04/09 11:26
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FIXX. Analyze the recent business situations of Homology Medicines through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FIXX stock price target is 27.00 with a high estimate of 37.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 154
Institutional Holdings: 31.17M
% Owned: 54.82%
Shares Outstanding: 56.86M
TypeInstitutionsShares
Increased
33
2.57M
New
16
479.88K
Decreased
33
3.08M
Sold Out
17
3.89M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.51%
Pharmaceuticals & Medical Research
-0.46%
Key Executives
President/Chief Executive Officer/Director/Primary Contact
Arthur Tzianabos
Chief Financial Officer/Treasurer/Secretary
W. Bradford Smith
Chief Operating Officer
Sam Rasty
Chief Operating Officer
Tim Kelly
Chief Scientific Officer
Albert Seymour
Other
Gabriel Cohn
Director
Jeffrey Poulton
Independent Director
Steven Gillis
Independent Director
Richard Gregory
Independent Director
Kush Parmar
Independent Director
Matthew Patterson
Independent Director
Alise Reicin
Independent Director
Mary Thistle
No Data
About FIXX
Homology Medicines, Inc. is a genetic medicines company translating gene editing and gene therapy technology into treatments for patients with rare diseases. The Company is focused on developing a pipeline of new medicines that address and cure the underlying cause of monogenic diseases in the liver, central nervous system (CNS), bone marrow, lung and the eye. The Company’s lead product candidate, HMI-102 is a gene therapy for the treatment of phenylketonuria (PKU). Its PKU program is focused on adults using the gene therapy approach. The Company’s suite of 15 adeno-associated virus vectors (AAVHSCs) enables it to focus on a method of gene editing called gene correction. The Company’s diverse set of AAVHSCs allows it to precisely target, via a single intravenous injection, a wide range of disease-relevant tissues, including the liver, central nervous system, or CNS, bone marrow, lung, muscle and eye, across both modalities - gene editing and gene therapy.

Webull offers kinds of Homology Medicines Inc stock information, including NASDAQ:FIXX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FIXX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FIXX stock methods without spending real money on the virtual paper trading platform.